Salivary passage of 5-fluorouracil during continuous infusion
- PMID: 2736710
- DOI: 10.1007/BF00300243
Salivary passage of 5-fluorouracil during continuous infusion
Abstract
Plasmatic and salivary concentrations of 5-FU were investigated in ten patients given 5-day continuous infusions of 5-fluorouracil (5-FU) (1 g/m2/day). Measurable concentrations of salivary 5-FU were scattered ranging from 6 to 100 ng/ml. Between individual 5-FU concentrations in saliva and plasma the coefficient of correlation was low. The theoretically predicted ratios of 5-FU concentrations in saliva over those in plasma, calculated as a function of salivary pH, did not correlate with the observed ratios, the majority of which ranged between 0.1 and 0.5. Noteworthy, 8 of 10 patients exhibited a more or less pronounced increase in 5-FU salivary excretion during 5-day continuous i.v. infusions.
Similar articles
-
Salivary excretion of 5-fluorouracil. II. Fluctuation of saliva/plasma concentration ratio and salivary clearance during a constant rate intravenous infusion in beagle dogs.J Pharmacobiodyn. 1988 Jun;11(6):438-43. doi: 10.1248/bpb1978.11.438. J Pharmacobiodyn. 1988. PMID: 3171885
-
Plasma and salivary pharmacokinetics of 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer receiving 5-FU bolus plus continuous infusion with high-dose folinic acid.Eur J Cancer. 1999 Feb;35(2):296-301. doi: 10.1016/s0959-8049(98)00318-9. Eur J Cancer. 1999. PMID: 10448274
-
Salivary excretion of 5-fluorouracil (5-FU). IV. Dependency of saliva/plasma concentration ratio and salivary clearance on plasma concentration of 5-FU during constant-rate intravenous infusion in rats.J Pharmacobiodyn. 1989 Mar;12(3):137-44. doi: 10.1248/bpb1978.12.137. J Pharmacobiodyn. 1989. PMID: 2760793
-
Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil.Clin Cancer Res. 1998 Sep;4(9):2085-8. Clin Cancer Res. 1998. PMID: 9748123
-
A review of GERCOD trials of bimonthly leucovorin plus 5-fluorouracil 48-h continuous infusion in advanced colorectal cancer: evolution of a regimen. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD).Eur J Cancer. 1998 Apr;34(5):619-26. doi: 10.1016/s0959-8049(97)00364-x. Eur J Cancer. 1998. PMID: 9713264 Review.
Cited by
-
Lysosomotropic properties of weakly basic anticancer agents promote cancer cell selectivity in vitro.PLoS One. 2012;7(11):e49366. doi: 10.1371/journal.pone.0049366. Epub 2012 Nov 7. PLoS One. 2012. PMID: 23145164 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources